GlassScriptPhysician profile
Ann M Lucas
NPI 1750305629
$3,999.27
in general payments reported to CMS, 2019-2025
34 companies · $635 in 2025
The $635 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $151 · 2021: $117 · 2022: $851 · 2023: $939 · 2024: $808 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,381.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $999.65 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $408.98 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $308.94 | 2019-2023 | Farxiga |
| Pfizer INC. | $277.89 | 2022-2025 | |
| Dexcom, INC. | $235.20 | 2022-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $219.62 | 2019-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $170.75 | 2019-2024 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $159.85 | 2019-2023 | |
| Amgen INC. | $137.89 | 2022-2023 | Evenity, Prolia, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $100.81 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $93.88 | 2019-2025 | Gardasil 9, M-M-R II, Rotateq |
| Sage Therapeutics, LLC | $90.30 | 2024-2025 | Zurzuvae |
| Janssen Pharmaceuticals, INC | $81.20 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $75.59 | 2019-2025 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $68.19 | 2022-2024 | Rexulti |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $60.52 | 2024 | Rexulti |
| Amarin Pharma, INC. | $54.44 | 2020-2021 | |
| Ge Healthcare | $53.38 | 2022-2024 | |
| Neurelis, INC. | $40.22 | 2025 | Valtoco |
| Sanofi Pasteur INC. | $39.23 | 2023-2024 | |
| Novo Nordisk INC | $38.91 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $36.86 | 2025 | Qelbree |
| Biohaven Pharmaceutical Holding Company LTD. | $36.30 | 2022 | |
| Exact Sciences Corporation | $31.36 | 2023-2024 | Cologuard Collection Kit |
| Alkermes, INC. | $30.65 | 2020-2025 | Vivitrol |
| Glaxosmithkline, LLC. | $30.23 | 2019 | |
| Organon LLC | $19.44 | 2024 | |
| Allergan, INC. | $18.19 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.19 | 2025 | Zoryve |
| Xeris Pharmaceuticals, INC. | $14.17 | 2024 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $14.17 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $13.07 | 2023 | Crysvita |
| Neurocrine Biosciences, INC. | $12.62 | 2022 | |
| Ironshore Pharmaceuticals INC. | $12.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Lucas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.